Beyond rNPV Valuations

Many valuation purists believe that a risk-adjusted net present value (rNPV) is the be-all and end-all of the value of a pharmaceutical asset. After all, it captures all the best insights into future...
Learn More

For pharma & biotech, what's the value of a valuation?

When a client approaches us about conducting a valuation for them, our first question is always: why? If, for example, the reason is to help support them in a partnering negotiation, we proceed...
Learn More

What Happens to Pharma Valuations as Interest Rates Rise?

Everyone familiar with the risk-adjusted net present value method (rNPV) knows automatically that valuations decrease as the discount rate increases. This is indeed a fundamental tenet of the...
Learn More

Light Due Diligence: A Contradiction in Terms?

Alacrita has established itself as an industry specialist in due diligence (DD), conducting over 25 DD assignments per year, across therapeutic areas and technologies. Sometimes a prospective clients...
Learn More

Pipeline asset valuation: garbage in – garbage out

Methods of valuing pharmaceutical development-stage assets have been a perennial talking point for decades, and the advantages and disadvantages of each have been covered in numerous publications....
Learn More

The risk-reward balance in drug repurposing

Does drug repurposing overcome the hurdles and pitfalls in drug development? Having conducted several recent due diligence exercises in the repurposing space, we discuss the gems and the hidden...
Learn More

Routes to European Commercialisation in Europe

Title: Routes to Commercialisation in Europe Author: Anna Casse, Managing Partner Abstract In the past it was not extraordinary for US biotech companies to develop drugs in the US and to launch them...
Learn More

NASH Bubble?

Title: NASH Bubble? Author: Peter G. Traber, MD Non-alcoholic fatty liver disease (NAFLD) and Non-alcoholic steatohepatitis (NASH) have been the subject of intense interest in the biotech/pharma...
Learn More

How to start a biotech company

How to start a biotech company by Rob Johnson, Managing Partner and Jess Hearn, Consultant, at Alacrita
Learn More

How best to Prioritize the IP Portfolio in Universities, Charities and Research Funding Bodies?

by Saadia Basharat, PhD, Consultant, Alacrita
Learn More
1

Need biotech consulting support? We can help.

Contact us today to learn how our pharma & biotech consulting expertise can serve your project.

Contact us

Explore our biotech & life science consulting services

© 2009-24 Alacrita Holdings Limited  |   Pharma & Biotech Consulting

Alacrita Consulting 
2 Royal College St
London, UK
NW1 0NH

Registered in England & Wales.
No. 10530608


One Broadway
Floor 14
Cambridge, MA 02142

Registered in Massachusetts.